A Phase IIIB, Open-Label, Randomized, Multi-Center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r [atazanavir + ritonavir] in in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r [lopinavir/ritonavir] Based Regimen.

Trial Profile

A Phase IIIB, Open-Label, Randomized, Multi-Center Study Evaluating the Effect on Serum Lipids Following a Switch to ATV/r [atazanavir + ritonavir] in in HIV-1 Infected Subjects Who Have Achieved Virologic Suppression on a LPV/r [lopinavir/ritonavir] Based Regimen.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2010

At a glance

  • Drugs Atazanavir (Primary) ; Lopinavir; Ritonavir
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Most Recent Events

    • 14 Jul 2009 Actual end date changed from Oct 2005 to May 2006 as reported by ClinicalTrials.gov.
    • 15 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top